RIPK1 antibody

Catalog No. ABIN967308

Product Details anti-RIPK1 Antibody

Target: RIPK1 (Receptor (TNFRSF)-Interacting serine-threonine Kinase 1 (RIPK1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This RIPK1 antibody is un-conjugated

Application: Western Blotting (WB), Immunoprecipitation (IP)

Brand: BD Pharmingen™

Characteristics: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogen: truncated RIP fusion protein

Clone: G322-2

Isotype: IgG1 kappa

Application Details

Application Notes: Additional control lysate (ABIN968537) is sold separately.

Comment:

Related Products: ABIN968537

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store undiluted at -20°C.

References for anti-RIPK1 antibody (ABIN967308)

Stanger, Leder, Lee, Kim, Seed: "RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death." in: Cell, Vol. 81, Issue 4, pp. 513-23, (1995) (PubMed).

Target Details for RIPK1

Target: RIPK1 (Receptor (TNFRSF)-Interacting serine-threonine Kinase 1 (RIPK1))

Alternative Name: RIP (RIPK1 Products)

Background: RIP (receptor interacting protein) is a 74 kDa serine/threonine kinase which may be recruited to TNFR type 1 and Fas (CD95) receptor signal complexes following ligand binding. RIP interacts with other signal proteins within these complexes (e.g., RAIDD) and has also been shown to interact with pro-caspase-2. RIP contains an N-terminal kinase domain as well as a C-terminal death domain that is homologous to intracellular death domain of Fas. Over expression of RIP in vitro is sufficient to induce cell death, demonstrating that RIP functions as an apoptosis-inducing protein. Interaction of the Fas death domain with other intracellular proteins like RIP is an important step leading to downstream components in apoptotic signaling pathways. Clone G322-2 recognizes human RIP. A recombinant truncated human RIP:tagged fusion protein, lacking the kinase domain of RIP, was used as immunogen. The specificity of the antibody was verified by ELISA, immunoprecipitation and western blot analysis. The antibody is routinely tested by western blot analysis in human Jurkat T cells where it recognizes RIP as a 74 kDa band. Smaller molecular weight breakdown bands of ~30 kDa, 22 kDa, and/or 16 kDa are sometimes observed.

Molecular Weight: 74 kDa

Pathways: NF-kappaB Signaling, Apoptosis, Caspase Cascade in Apoptosis, TLR Signaling, Activation of Innate immune Response, Inositol Metabolic Process, Positive Regulation of Endopeptidase Activity, Hepatitis C, Protein targeting to Nucleus, Toll-Like Receptors Cascades, Negative Regulation of intrinsic apoptotic Signaling, SARS-CoV-2 Protein Interactome, Ubiquitin Proteasome Pathway